院外心脏骤停复苏后休克:肾上腺素与去甲肾上腺素输注的心律失常风险
这项回顾性队列研究纳入2018年5月5日至2022年1月31日期间美国多家医院收治的221例院外心脏骤停(OHCA)后复苏后休克患者,在自主循环恢复(ROSC)后6小时内接受肾上腺素或去甲肾上腺素持续输注。单变量分析(47.1% vs 41.7%,OR 1.24,95% CI 0.71-2.20)和多变量分析(OR 1.34,95% CI 0.68-2.62)均显示两组快速性心律失常发生率无差异。肾上腺素组院内死亡(90.0% vs 54.3%,OR 6.21,95% CI 2.37-16.25,p<0.001)和住院期间再骤停(55.7% vs 14.6%,OR 5.77,95% CI 2.74-12.18,p<0.001)均更高。作者认为结果支持去甲肾上腺素可能为OHCA后复苏后休克的首选血管加压药。
要点
- OHCA后复苏后休克患者中,肾上腺素与去甲肾上腺素输注的临床显著快速性心律失常无统计学差异(单变量47.1% vs 41.7%,OR 1.24,95% CI 0.71-2.20;多变量OR 1.34,95% CI 0.68-2.62)。
- 肾上腺素组院内死亡率90.0%,去甲肾上腺素组54.3%(OR 6.21,95% CI 2.37-16.25,p<0.001)。
- 肾上腺素组住院期间再骤停率55.7%,去甲肾上腺素组14.6%(OR 5.77,95% CI 2.74-12.18,p<0.001)。
- 作者认为去甲肾上腺素可能是OHCA后复苏后休克的首选血管加压药。
适用人群与场景
- 成人OHCA患者,ROSC后6小时内因复苏后休克接受肾上腺素或去甲肾上腺素持续输注。
- 来自美国多家医院组成的大型多站点医疗系统。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量221例;美国大型多站点医疗系统。
- 纳入2018年5月5日至2022年1月31日收治的OHCA后复苏后休克患者,在ROSC后6小时内接受肾上腺素或去甲肾上腺素输注。
- 主要终点:临床显著快速性心律失常发生率,肾上腺素组47.1% vs 去甲肾上腺素组41.7%,OR 1.24,95% CI 0.71-2.20(单变量);多变量分析OR 1.34,95% CI 0.68-2.62。
- 院内死亡:肾上腺素组90.0% vs 去甲肾上腺素组54.3%,OR 6.21,95% CI 2.37-16.25,p<0.001。
- 住院期间再骤停:肾上腺素组55.7% vs 去甲肾上腺素组14.6%,OR 5.77,95% CI 2.74-12.18,p<0.001。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
对床旁实践的改变
- 作者认为,去甲肾上腺素可能是OHCA后复苏后休克患者的首选血管加压药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the rates of clinically significant tachyarrhythmias and mortality in the management of post-resuscitative shock after return of spontaneous circulation (ROSC) in patients with out-of-hospital cardiac arrest (OHCA) who receive a continuous epinephrine versus norepinephrine infusion.
DESIGN: Retrospective cohort study.
SETTING: A large multi-site health system with hospitals across the United States.
PATIENTS: Adult patients admitted for OHCA with post-resuscitative shock managed with either epinephrine or norepinephrine infusions within 6 h of ROSC.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Between May 5th, 2018, to January 31st, 2022, there were 221 patients admitted for OHCA who received post-resuscitative epinephrine or norepinephrine infusions. There was no difference in the rate of tachyarrhythmias between epinephrine and norepinephrine infusion in univariate (47.1% vs 41.7%, OR 1.24, 95% CI 0.71-2.20) or multivariable analysis (OR 1.34, 95% CI 0.68-2.62). Patients treated with epinephrine were more likely to die during hospitalization than those treated with norepinephrine (90.0% vs 54.3%, OR 6.21, 95% CI 2.37-16.25, p < 0.001). Epinephrine treated patients were more likely to have re-arrest during hospital admission (55.7% vs 14.6%, OR 5.77, 95% CI 2.74-12.18, p < 0.001).
CONCLUSION: There was no statistically significant difference in clinically significant cardiac tachyarrhythmias in post-OHCA patients treated with epinephrine versus norepinephrine infusions after ROSC. Re-arrest rates and in-hospital mortality were higher in patients who received epinephrine infusions in the first 6 h post-ROSC. Results of this study add to the literature suggesting norepinephrine may be the vasopressor of choice in post-OHCA patients with post-resuscitative shock after ROSC.
参考来源
- Normand S, Matthews C, Brown CS, et al. Risk of arrhythmia in post-resuscitative shock after out-of-hospital cardiac arrest with epinephrine versus norepinephrine. Am J Emerg Med. 2023. PMID: 38104386. doi:10.1016/j.ajem.2023.12.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。